NY-UNITED-FIRST-PARTNERS
United First Partners (“UFP”), a leading independent Equity Research, Advisory and Brokerage firm, providing event driven and special situations equities research and execution, adds four analysts in London and New York.
UFP has hired Bruno Burki, as a London based research salesperson. Prior to joining UFP, Bruno was head of event driven research at Square Global Markets and previously a senior Associate in the UK M&A team at Barclays in London, where he advised corporates and financial sponsors on a wide range of strategic transactions. Bruno notably advised ENOC in their acquisition of the minorities’ stake they didn't own in Dragon Oil, and International Power in their defence against GDF.
In addition, UFP hired Patryk Basiewicz (CFA) as a special situations analyst. Patryk joined UFP from Olivetree where he was a TMT Sector Strategist. At Olivetree, Patrick was responsible for formulation of investment ideas in European TMT equity space and handled fundamental aspects of Olivetree’s Event-driven product. Previous roles include buyside analyst positions as well as management consultant at McKinsey & Co.
The London unit also hired Josh Rosen as a special situations analyst. Prior to joining UFP, Josh was an Investment Banking Associate at Citigroup in London in the FIG group, where he worked on large-cap M&A deals across the banking and insurance sectors, as well as IPOs and capital markets financing. Prior to this, Josh held roles in Wealth & Investment Management at Citigroup and Barclays in London and Geneva where he advised Ultra High Net Worth clients.
In New York, UFP reinforced its research team with the hiring of Maggie Bishop. She joins UFP from Wells Fargo Securities in Houston where she was an Analyst in the Energy Investment Banking Group, involved in a wide variety of mergers and acquisitions, capital markets financings and strategic advisory assignments for clients across the upstream, midstream, and oilfield services sectors.
United First Partners CEO Stephane Mardel commented: “One of UFP group’s key strength is the delivery of unique, actionable and thorough research work across the globe. With the hiring of Bruno, Patryk, Josh and Maggie, UFP continues to offer one of the largest special situations research platform on the street, with diversified talents, covering multiple industries. These new hires help complement the skills of our existing established research teams in London and New York, demonstrating our commitment to producing top tier special situations research, and our desire to work relentlessly to maximise value for our clients.”
About UFP and Mariana UFP
United First Partners is an independent global financial services firm, with a strong reputation and leading position in the Equities and Derivatives space. UFP’s award winning research reflects UFP’s commitment to excellence in Special Situations Research, providing best in class and in-depth research coverage on companies where specific events may act as a catalyst for material price actions, using fundamental analysis and unique in-house legal resources. United First Partners and Mariana entered into a strategic alliance in May 2017 to generate synergies across the group’s complementary business lines and play an active role in the industry consolidation. Mariana UFP offers comprehensive cross-asset services in Europe & Australia (through Mariana UFP LLP, regulated by the FCA), in North America (through United First Partners LLC, SEC regulated and member of FINRA and SIPC) and in the UAE (through UFP Capital Markets (DIFC) Limited, regulated by the DFSA). The Mariana UFP group also offers structured products, advisory and asset management services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181001005471/en/
Contact:
United First Partners Stephane Mardel +442030174330 stephane.mardel@utdfirst.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
